 | • レポートコード：MRC2-11QY12764 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、188ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は腫瘍壊死因子阻害薬のグローバル市場について調査・分析したレポートです。種類別（Cimzia（セルトリズマブペゴル）、Enbrel（エタネルセプト）、Humira（アダリムマブ）、Otezla（アプレミラスト）、Remicade（インフリキシマブ）、Simponi（ゴリムマブ））市場規模、用途別（診療所、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別腫瘍壊死因子阻害薬の競争状況、市場シェア ・世界の腫瘍壊死因子阻害薬市場：種類別市場規模 2015年-2020年（Cimzia（セルトリズマブペゴル）、Enbrel（エタネルセプト）、Humira（アダリムマブ）、Otezla（アプレミラスト）、Remicade（インフリキシマブ）、Simponi（ゴリムマブ）） ・世界の腫瘍壊死因子阻害薬市場：種類別市場規模予測 2021年-2026年（Cimzia（セルトリズマブペゴル）、Enbrel（エタネルセプト）、Humira（アダリムマブ）、Otezla（アプレミラスト）、Remicade（インフリキシマブ）、Simponi（ゴリムマブ）） ・世界の腫瘍壊死因子阻害薬市場：用途別市場規模 2015年-2020年（診療所、病院、その他） ・世界の腫瘍壊死因子阻害薬市場：用途別市場規模予測 2021年-2026年（診療所、病院、その他） ・北米の腫瘍壊死因子阻害薬市場分析：米国、カナダ ・ヨーロッパの腫瘍壊死因子阻害薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの腫瘍壊死因子阻害薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の腫瘍壊死因子阻害薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの腫瘍壊死因子阻害薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Apogenix、AryoGen Biopharma、Bionovis、CASI Pharmaceuticals、Celltrion、Celgene Corporation、Delenex Therapeutics、Dexa Medica、EPIRUS Biopharmaceuticals、Janssen Biotech、GlaxoSmithKline、HanAll Biopharma、Intas Pharmaceuticals、LEO Pharma、LG Life Sciences、MedImmune、Momenta Pharmaceuticals、Novartis、PROBIOMED、Reliance Life Sciences、Sandoz、Samsung Bioepis、Sanofi-Aventis、Shanghai CP Guojian Pharmaceutical、Shanghai Pharmaceuticals、Simcere Pharmaceutical、Toyama Chemical、Tsumura、UCB、Zydus Cadila ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Drug Market
The global Tumor Necrosis Factor Inhibitors Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Tumor Necrosis Factor Inhibitors Drug Scope and Market Size
Tumor Necrosis Factor Inhibitors Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Necrosis Factor Inhibitors Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Tumor Necrosis Factor Inhibitors Drug market is segmented into
Cimzia (Certolizumab Pegol)
Enbrel (Etanercept)
Humira ( Adalimumab)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
Segment by Application, the Tumor Necrosis Factor Inhibitors Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Tumor Necrosis Factor Inhibitors Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Tumor Necrosis Factor Inhibitors Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Tumor Necrosis Factor Inhibitors Drug Market Share Analysis
Tumor Necrosis Factor Inhibitors Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Tumor Necrosis Factor Inhibitors Drug business, the date to enter into the Tumor Necrosis Factor Inhibitors Drug market, Tumor Necrosis Factor Inhibitors Drug product introduction, recent developments, etc.
The major vendors covered:
Apogenix
AryoGen Biopharma
Bionovis
CASI Pharmaceuticals
Celltrion
Celgene Corporation
Delenex Therapeutics
Dexa Medica
EPIRUS Biopharmaceuticals
Janssen Biotech
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
LG Life Sciences
MedImmune
Momenta Pharmaceuticals
Novartis
PROBIOMED
Reliance Life Sciences
Sandoz
Samsung Bioepis
Sanofi-Aventis
Shanghai CP Guojian Pharmaceutical
Shanghai Pharmaceuticals
Simcere Pharmaceutical
Toyama Chemical
Tsumura
UCB
Zydus Cadila
1 Study Coverage
1.1 Tumor Necrosis Factor Inhibitors Drug Product Introduction
1.2 Market Segments
1.3 Key Tumor Necrosis Factor Inhibitors Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type
1.4.2 Cimzia (Certolizumab Pegol)
1.4.3 Enbrel (Etanercept)
1.4.4 Humira ( Adalimumab)
1.4.5 Otezla (Apremilast)
1.4.6 Remicade (Infliximab)
1.4.7 Simponi (Golimumab)
1.5 Market by Application
1.5.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size, Estimates and Forecasts
2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue 2015-2026
2.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales 2015-2026
2.2 Global Tumor Necrosis Factor Inhibitors Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Tumor Necrosis Factor Inhibitors Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Tumor Necrosis Factor Inhibitors Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Tumor Necrosis Factor Inhibitors Drug Competitor Landscape by Players
3.1 Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers
3.1.1 Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers (2015-2020)
3.1.2 Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers
3.2.1 Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2015-2020)
3.2.2 Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Tumor Necrosis Factor Inhibitors Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Drug Revenue in 2019
3.2.5 Global Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Tumor Necrosis Factor Inhibitors Drug Price by Manufacturers
3.4 Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution, Product Types
3.4.1 Tumor Necrosis Factor Inhibitors Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Type
3.4.3 Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Type (2015-2020)
4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020)
4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2015-2020)
4.1.3 Tumor Necrosis Factor Inhibitors Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Type (2021-2026)
4.2.3 Tumor Necrosis Factor Inhibitors Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Tumor Necrosis Factor Inhibitors Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Application (2015-2020)
5.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020)
5.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2015-2020)
5.1.3 Tumor Necrosis Factor Inhibitors Drug Price by Application (2015-2020)
5.2 Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Tumor Necrosis Factor Inhibitors Drug by Country
6.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Country
6.1.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Type
6.3 North America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitors Drug by Country
7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country
7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Type
7.3 Europe Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug by Region
8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region
8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Type
8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Tumor Necrosis Factor Inhibitors Drug by Country
9.1.1 Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country
9.1.2 Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Type
9.3 Central & South America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug by Country
10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country
10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Type
10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Apogenix
11.1.1 Apogenix Corporation Information
11.1.2 Apogenix Description and Business Overview
11.1.3 Apogenix Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Products Offered
11.1.5 Apogenix Related Developments
11.2 AryoGen Biopharma
11.2.1 AryoGen Biopharma Corporation Information
11.2.2 AryoGen Biopharma Description and Business Overview
11.2.3 AryoGen Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Products Offered
11.2.5 AryoGen Biopharma Related Developments
11.3 Bionovis
11.3.1 Bionovis Corporation Information
11.3.2 Bionovis Description and Business Overview
11.3.3 Bionovis Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Products Offered
11.3.5 Bionovis Related Developments
11.4 CASI Pharmaceuticals
11.4.1 CASI Pharmaceuticals Corporation Information
11.4.2 CASI Pharmaceuticals Description and Business Overview
11.4.3 CASI Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
11.4.5 CASI Pharmaceuticals Related Developments
11.5 Celltrion
11.5.1 Celltrion Corporation Information
11.5.2 Celltrion Description and Business Overview
11.5.3 Celltrion Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Products Offered
11.5.5 Celltrion Related Developments
11.6 Celgene Corporation
11.6.1 Celgene Corporation Corporation Information
11.6.2 Celgene Corporation Description and Business Overview
11.6.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Products Offered
11.6.5 Celgene Corporation Related Developments
11.7 Delenex Therapeutics
11.7.1 Delenex Therapeutics Corporation Information
11.7.2 Delenex Therapeutics Description and Business Overview
11.7.3 Delenex Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Products Offered
11.7.5 Delenex Therapeutics Related Developments
11.8 Dexa Medica
11.8.1 Dexa Medica Corporation Information
11.8.2 Dexa Medica Description and Business Overview
11.8.3 Dexa Medica Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Products Offered
11.8.5 Dexa Medica Related Developments
11.9 EPIRUS Biopharmaceuticals
11.9.1 EPIRUS Biopharmaceuticals Corporation Information
11.9.2 EPIRUS Biopharmaceuticals Description and Business Overview
11.9.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
11.9.5 EPIRUS Biopharmaceuticals Related Developments
11.10 Janssen Biotech
11.10.1 Janssen Biotech Corporation Information
11.10.2 Janssen Biotech Description and Business Overview
11.10.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Products Offered
11.10.5 Janssen Biotech Related Developments
11.1 Apogenix
11.1.1 Apogenix Corporation Information
11.1.2 Apogenix Description and Business Overview
11.1.3 Apogenix Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Products Offered
11.1.5 Apogenix Related Developments
11.12 HanAll Biopharma
11.12.1 HanAll Biopharma Corporation Information
11.12.2 HanAll Biopharma Description and Business Overview
11.12.3 HanAll Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.12.4 HanAll Biopharma Products Offered
11.12.5 HanAll Biopharma Related Developments
11.13 Intas Pharmaceuticals
11.13.1 Intas Pharmaceuticals Corporation Information
11.13.2 Intas Pharmaceuticals Description and Business Overview
11.13.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Intas Pharmaceuticals Products Offered
11.13.5 Intas Pharmaceuticals Related Developments
11.14 LEO Pharma
11.14.1 LEO Pharma Corporation Information
11.14.2 LEO Pharma Description and Business Overview
11.14.3 LEO Pharma Sales, Revenue and Gross Margin (2015-2020)
11.14.4 LEO Pharma Products Offered
11.14.5 LEO Pharma Related Developments
11.15 LG Life Sciences
11.15.1 LG Life Sciences Corporation Information
11.15.2 LG Life Sciences Description and Business Overview
11.15.3 LG Life Sciences Sales, Revenue and Gross Margin (2015-2020)
11.15.4 LG Life Sciences Products Offered
11.15.5 LG Life Sciences Related Developments
11.16 MedImmune
11.16.1 MedImmune Corporation Information
11.16.2 MedImmune Description and Business Overview
11.16.3 MedImmune Sales, Revenue and Gross Margin (2015-2020)
11.16.4 MedImmune Products Offered
11.16.5 MedImmune Related Developments
11.17 Momenta Pharmaceuticals
11.17.1 Momenta Pharmaceuticals Corporation Information
11.17.2 Momenta Pharmaceuticals Description and Business Overview
11.17.3 Momenta Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Momenta Pharmaceuticals Products Offered
11.17.5 Momenta Pharmaceuticals Related Developments
11.18 Novartis
11.18.1 Novartis Corporation Information
11.18.2 Novartis Description and Business Overview
11.18.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Novartis Products Offered
11.18.5 Novartis Related Developments
11.19 PROBIOMED
11.19.1 PROBIOMED Corporation Information
11.19.2 PROBIOMED Description and Business Overview
11.19.3 PROBIOMED Sales, Revenue and Gross Margin (2015-2020)
11.19.4 PROBIOMED Products Offered
11.19.5 PROBIOMED Related Developments
11.20 Reliance Life Sciences
11.20.1 Reliance Life Sciences Corporation Information
11.20.2 Reliance Life Sciences Description and Business Overview
11.20.3 Reliance Life Sciences Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Reliance Life Sciences Products Offered
11.20.5 Reliance Life Sciences Related Developments
11.21 Sandoz
11.21.1 Sandoz Corporation Information
11.21.2 Sandoz Description and Business Overview
11.21.3 Sandoz Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Sandoz Products Offered
11.21.5 Sandoz Related Developments
11.22 Samsung Bioepis
11.22.1 Samsung Bioepis Corporation Information
11.22.2 Samsung Bioepis Description and Business Overview
11.22.3 Samsung Bioepis Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Samsung Bioepis Products Offered
11.22.5 Samsung Bioepis Related Developments
11.23 Sanofi-Aventis
11.23.1 Sanofi-Aventis Corporation Information
11.23.2 Sanofi-Aventis Description and Business Overview
11.23.3 Sanofi-Aventis Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Sanofi-Aventis Products Offered
11.23.5 Sanofi-Aventis Related Developments
11.24 Shanghai CP Guojian Pharmaceutical
11.24.1 Shanghai CP Guojian Pharmaceutical Corporation Information
11.24.2 Shanghai CP Guojian Pharmaceutical Description and Business Overview
11.24.3 Shanghai CP Guojian Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.24.4 Shanghai CP Guojian Pharmaceutical Products Offered
11.24.5 Shanghai CP Guojian Pharmaceutical Related Developments
11.25 Shanghai Pharmaceuticals
11.25.1 Shanghai Pharmaceuticals Corporation Information
11.25.2 Shanghai Pharmaceuticals Description and Business Overview
11.25.3 Shanghai Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.25.4 Shanghai Pharmaceuticals Products Offered
11.25.5 Shanghai Pharmaceuticals Related Developments
11.26 Simcere Pharmaceutical
11.26.1 Simcere Pharmaceutical Corporation Information
11.26.2 Simcere Pharmaceutical Description and Business Overview
11.26.3 Simcere Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.26.4 Simcere Pharmaceutical Products Offered
11.26.5 Simcere Pharmaceutical Related Developments
11.27 Toyama Chemical
11.27.1 Toyama Chemical Corporation Information
11.27.2 Toyama Chemical Description and Business Overview
11.27.3 Toyama Chemical Sales, Revenue and Gross Margin (2015-2020)
11.27.4 Toyama Chemical Products Offered
11.27.5 Toyama Chemical Related Developments
11.28 Tsumura
11.28.1 Tsumura Corporation Information
11.28.2 Tsumura Description and Business Overview
11.28.3 Tsumura Sales, Revenue and Gross Margin (2015-2020)
11.28.4 Tsumura Products Offered
11.28.5 Tsumura Related Developments
11.29 UCB
11.29.1 UCB Corporation Information
11.29.2 UCB Description and Business Overview
11.29.3 UCB Sales, Revenue and Gross Margin (2015-2020)
11.29.4 UCB Products Offered
11.29.5 UCB Related Developments
11.30 Zydus Cadila
11.30.1 Zydus Cadila Corporation Information
11.30.2 Zydus Cadila Description and Business Overview
11.30.3 Zydus Cadila Sales, Revenue and Gross Margin (2015-2020)
11.30.4 Zydus Cadila Products Offered
11.30.5 Zydus Cadila Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Tumor Necrosis Factor Inhibitors Drug Market Estimates and Projections by Region
12.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Regions 2021-2026
12.2 North America Tumor Necrosis Factor Inhibitors Drug Market Size Forecast (2021-2026)
12.2.1 North America: Tumor Necrosis Factor Inhibitors Drug Sales Forecast (2021-2026)
12.2.2 North America: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast (2021-2026)
12.2.3 North America: Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Tumor Necrosis Factor Inhibitors Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Tumor Necrosis Factor Inhibitors Drug Sales Forecast (2021-2026)
12.3.2 Europe: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Tumor Necrosis Factor Inhibitors Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Tumor Necrosis Factor Inhibitors Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Tumor Necrosis Factor Inhibitors Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Tumor Necrosis Factor Inhibitors Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Tumor Necrosis Factor Inhibitors Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Tumor Necrosis Factor Inhibitors Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Tumor Necrosis Factor Inhibitors Drug Market Segments
Table 2. Ranking of Global Top Tumor Necrosis Factor Inhibitors Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Cimzia (Certolizumab Pegol)
Table 5. Major Manufacturers of Enbrel (Etanercept)
Table 6. Major Manufacturers of Humira ( Adalimumab)
Table 7. Major Manufacturers of Otezla (Apremilast)
Table 8. Major Manufacturers of Remicade (Infliximab)
Table 9. Major Manufacturers of Simponi (Golimumab)
Table 10. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Tumor Necrosis Factor Inhibitors Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Tumor Necrosis Factor Inhibitors Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Tumor Necrosis Factor Inhibitors Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2019)
Table 19. Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Price (2015-2020) (USD/Pcs)
Table 22. Tumor Necrosis Factor Inhibitors Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Type
Table 24. Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2015-2020)
Table 28. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2015-2020)
Table 30. Tumor Necrosis Factor Inhibitors Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Application (2015-2020)
Table 33. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2015-2020)
Table 35. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2015-2020)
Table 39. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
Table 73. Apogenix Corporation Information
Table 74. Apogenix Description and Major Businesses
Table 75. Apogenix Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Apogenix Product
Table 77. Apogenix Recent Development
Table 78. AryoGen Biopharma Corporation Information
Table 79. AryoGen Biopharma Description and Major Businesses
Table 80. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. AryoGen Biopharma Product
Table 82. AryoGen Biopharma Recent Development
Table 83. Bionovis Corporation Information
Table 84. Bionovis Description and Major Businesses
Table 85. Bionovis Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Bionovis Product
Table 87. Bionovis Recent Development
Table 88. CASI Pharmaceuticals Corporation Information
Table 89. CASI Pharmaceuticals Description and Major Businesses
Table 90. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. CASI Pharmaceuticals Product
Table 92. CASI Pharmaceuticals Recent Development
Table 93. Celltrion Corporation Information
Table 94. Celltrion Description and Major Businesses
Table 95. Celltrion Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Celltrion Product
Table 97. Celltrion Recent Development
Table 98. Celgene Corporation Corporation Information
Table 99. Celgene Corporation Description and Major Businesses
Table 100. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Celgene Corporation Product
Table 102. Celgene Corporation Recent Development
Table 103. Delenex Therapeutics Corporation Information
Table 104. Delenex Therapeutics Description and Major Businesses
Table 105. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Delenex Therapeutics Product
Table 107. Delenex Therapeutics Recent Development
Table 108. Dexa Medica Corporation Information
Table 109. Dexa Medica Description and Major Businesses
Table 110. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Dexa Medica Product
Table 112. Dexa Medica Recent Development
Table 113. EPIRUS Biopharmaceuticals Corporation Information
Table 114. EPIRUS Biopharmaceuticals Description and Major Businesses
Table 115. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. EPIRUS Biopharmaceuticals Product
Table 117. EPIRUS Biopharmaceuticals Recent Development
Table 118. Janssen Biotech Corporation Information
Table 119. Janssen Biotech Description and Major Businesses
Table 120. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Janssen Biotech Product
Table 122. Janssen Biotech Recent Development
Table 123. GlaxoSmithKline Corporation Information
Table 124. GlaxoSmithKline Description and Major Businesses
Table 125. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. GlaxoSmithKline Product
Table 127. GlaxoSmithKline Recent Development
Table 128. HanAll Biopharma Corporation Information
Table 129. HanAll Biopharma Description and Major Businesses
Table 130. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. HanAll Biopharma Product
Table 132. HanAll Biopharma Recent Development
Table 133. Intas Pharmaceuticals Corporation Information
Table 134. Intas Pharmaceuticals Description and Major Businesses
Table 135. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. Intas Pharmaceuticals Product
Table 137. Intas Pharmaceuticals Recent Development
Table 138. LEO Pharma Corporation Information
Table 139. LEO Pharma Description and Major Businesses
Table 140. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 141. LEO Pharma Product
Table 142. LEO Pharma Recent Development
Table 143. LG Life Sciences Corporation Information
Table 144. LG Life Sciences Description and Major Businesses
Table 145. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 146. LG Life Sciences Product
Table 147. LG Life Sciences Recent Development
Table 148. MedImmune Corporation Information
Table 149. MedImmune Description and Major Businesses
Table 150. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 151. MedImmune Product
Table 152. MedImmune Recent Development
Table 153. Momenta Pharmaceuticals Corporation Information
Table 154. Momenta Pharmaceuticals Description and Major Businesses
Table 155. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 156. Momenta Pharmaceuticals Product
Table 157. Momenta Pharmaceuticals Recent Development
Table 158. Novartis Corporation Information
Table 159. Novartis Description and Major Businesses
Table 160. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 161. Novartis Product
Table 162. Novartis Recent Development
Table 163. PROBIOMED Corporation Information
Table 164. PROBIOMED Description and Major Businesses
Table 165. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 166. PROBIOMED Product
Table 167. PROBIOMED Recent Development
Table 168. Reliance Life Sciences Corporation Information
Table 169. Reliance Life Sciences Description and Major Businesses
Table 170. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 171. Reliance Life Sciences Product
Table 172. Reliance Life Sciences Recent Development
Table 173. Sandoz Corporation Information
Table 174. Sandoz Description and Major Businesses
Table 175. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 176. Sandoz Product
Table 177. Sandoz Recent Development
Table 178. Samsung Bioepis Corporation Information
Table 179. Samsung Bioepis Description and Major Businesses
Table 180. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 181. Samsung Bioepis Product
Table 182. Samsung Bioepis Recent Development
Table 183. Sanofi-Aventis Corporation Information
Table 184. Sanofi-Aventis Description and Major Businesses
Table 185. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 186. Sanofi-Aventis Product
Table 187. Sanofi-Aventis Recent Development
Table 188. Shanghai CP Guojian Pharmaceutical Corporation Information
Table 189. Shanghai CP Guojian Pharmaceutical Description and Major Businesses
Table 190. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 191. Shanghai CP Guojian Pharmaceutical Product
Table 192. Shanghai CP Guojian Pharmaceutical Recent Development
Table 193. Shanghai Pharmaceuticals Corporation Information
Table 194. Shanghai Pharmaceuticals Description and Major Businesses
Table 195. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 196. Shanghai Pharmaceuticals Product
Table 197. Shanghai Pharmaceuticals Recent Development
Table 198. Simcere Pharmaceutical Corporation Information
Table 199. Simcere Pharmaceutical Description and Major Businesses
Table 200. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 201. Simcere Pharmaceutical Product
Table 202. Simcere Pharmaceutical Recent Development
Table 203. Toyama Chemical Corporation Information
Table 204. Toyama Chemical Description and Major Businesses
Table 205. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 206. Toyama Chemical Product
Table 207. Toyama Chemical Recent Development
Table 208. Tsumura Corporation Information
Table 209. Tsumura Description and Major Businesses
Table 210. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 211. Tsumura Product
Table 212. Tsumura Recent Development
Table 213. UCB Corporation Information
Table 214. UCB Description and Major Businesses
Table 215. UCB Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 216. UCB Product
Table 217. UCB Recent Development
Table 218. Zydus Cadila Corporation Information
Table 219. Zydus Cadila Description and Major Businesses
Table 220. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 221. Zydus Cadila Product
Table 222. Zydus Cadila Recent Development
Table 223. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 224. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Regions (2021-2026)
Table 225. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 226. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 227. North America: Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 228. North America: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 229. Europe: Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 230. Europe: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 231. Asia Pacific: Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 232. Asia Pacific: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 233. Latin America: Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 234. Latin America: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 235. Middle East and Africa: Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 236. Middle East and Africa: Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 237. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 238. Key Challenges
Table 239. Market Risks
Table 240. Main Points Interviewed from Key Tumor Necrosis Factor Inhibitors Drug Players
Table 241. Tumor Necrosis Factor Inhibitors Drug Customers List
Table 242. Tumor Necrosis Factor Inhibitors Drug Distributors List
Table 243. Research Programs/Design for This Report
Table 244. Key Data Information from Secondary Sources
Table 245. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Drug Product Picture
Figure 2. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Cimzia (Certolizumab Pegol) Product Picture
Figure 4. Enbrel (Etanercept) Product Picture
Figure 5. Humira ( Adalimumab) Product Picture
Figure 6. Otezla (Apremilast) Product Picture
Figure 7. Remicade (Infliximab) Product Picture
Figure 8. Simponi (Golimumab) Product Picture
Figure 9. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Tumor Necrosis Factor Inhibitors Drug Report Years Considered
Figure 14. Global Tumor Necrosis Factor Inhibitors Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Tumor Necrosis Factor Inhibitors Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Tumor Necrosis Factor Inhibitors Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region in 2019
Figure 19. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region in 2019
Figure 21. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Tumor Necrosis Factor Inhibitors Drug Revenue in 2019
Figure 23. Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2019
Figure 26. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type in 2019
Figure 28. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Price Range (2015-2020)
Figure 29. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2019
Figure 31. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application in 2019
Figure 33. North America Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2019
Figure 36. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Tumor Necrosis Factor Inhibitors Drug Market Share by Type in 2019
Figure 42. North America Tumor Necrosis Factor Inhibitors Drug Market Share by Application in 2019
Figure 43. Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2019
Figure 46. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2019
Figure 47. Germany Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Tumor Necrosis Factor Inhibitors Drug Market Share by Type in 2019
Figure 58. Europe Tumor Necrosis Factor Inhibitors Drug Market Share by Application in 2019
Figure 59. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region in 2019
Figure 63. China Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Share by Type in 2019
Figure 86. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Share by Application in 2019
Figure 87. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2019
Figure 90. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Tumor Necrosis Factor Inhibitors Drug Market Share by Type in 2019
Figure 98. Latin America Tumor Necrosis Factor Inhibitors Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Tumor Necrosis Factor Inhibitors Drug Sal
腫瘍壊死因子α阻害剤の世界市場（～2026年） The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), i…- 腫瘍壊死因子阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Market The global Tumor Necrosis Factor Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tumor Necrosis Factor Inhibitors Scope and Market…
- 神経内分泌腫瘍治療薬の世界市場（～2026年） Market Analysis and Insights: Global Neuroendocrine Tumor Drug Market The global Neuroendocrine Tumor Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Neuroendocrine Tumor Drug Scope and Market Size Neuroendocrine …
- 皮膚壊死治療の世界市場（～2026年） Acute cutaneous necrosis can be defined as a skin disease with sudden onset of tissue death that results in significant morbidity and is usually, but not always, excruciatingly painful. Early diagnosis can allow for early therapy and can decrease the chances of morbidity and loss of life. A thorough…
- 無血管性壊死（AVN）の世界市場（～2026年） Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to interruption of the blood supply. Early on there may be no symptoms. Gradually joint pain may develop which may limit the ability to move. Complication may include collapse of the bone or nearby jo…